Literature DB >> 24565000

Role of C-reactive protein in schizophrenia: an overview.

Bisu Singh1, Tapas Kumar Chaudhuri2.   

Abstract

Over the years, schizophrenia is speculated to be associated with immune or inflammatory reactions mediated by cytokines. It is proposed that chronic inflammation might damage the micro-vascular system of brain and hamper cerebral blood flow. Scientific evidence suggests that an increase of stress hormone like norepinephrine may activate the inflammatory arm of the immune system and trigger the expression of genes that cause chronic, low-grade inflammation. Thus, studies were conducted to decipher the potentiality of CRP as a marker for inflammation in schizophrenia. This article reviews the findings of CRP in schizophrenia, and the limitations of the previous studies have been discussed. The importance of simultaneous study of CRP modulating cytokines and CRP gene polymorphism in the study of serum or plasma level of CRP has been emphasized.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  C-reactive protein; IL-6; Inflammation; Schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 24565000     DOI: 10.1016/j.psychres.2014.02.004

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  23 in total

1.  Inflammatory Markers in Recent Onset Psychosis and Chronic Schizophrenia.

Authors:  Faith Dickerson; Cassie Stallings; Andrea Origoni; Jennifer Schroeder; Emily Katsafanas; Lucy Schweinfurth; Christina Savage; Sunil Khushalani; Robert Yolken
Journal:  Schizophr Bull       Date:  2015-08-19       Impact factor: 9.306

2.  Shared Immune and Repair Markers During Experimental Toxoplasma Chronic Brain Infection and Schizophrenia.

Authors:  Jakub Tomasik; Tracey L Schultz; Wolfgang Kluge; Robert H Yolken; Sabine Bahn; Vern B Carruthers
Journal:  Schizophr Bull       Date:  2015-09-20       Impact factor: 9.306

3.  Genome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic Risks.

Authors:  Richard Sherva; Qian Wang; Henry Kranzler; Hongyu Zhao; Ryan Koesterer; Aryeh Herman; Lindsay A Farrer; Joel Gelernter
Journal:  JAMA Psychiatry       Date:  2016-05-01       Impact factor: 21.596

4.  Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study.

Authors:  M Faugere; J A Micoulaud-Franchi; M Alessandrini; R Richieri; C Faget-Agius; P Auquier; C Lançon; L Boyer
Journal:  Sci Rep       Date:  2015-06-04       Impact factor: 4.379

5.  Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation.

Authors:  Dimitrios Avramopoulos; Brad D Pearce; John McGrath; Paula Wolyniec; Ruihua Wang; Nicole Eckart; Alexandros Hatzimanolis; Fernando S Goes; Gerald Nestadt; Jennifer Mulle; Karen Coneely; Myfanwy Hopkins; Ingo Ruczinski; Robert Yolken; Ann E Pulver
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

6.  Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study.

Authors:  Bram P Prins; Ali Abbasi; Anson Wong; Ahmad Vaez; Ilja Nolte; Nora Franceschini; Philip E Stuart; Javier Guterriez Achury; Vanisha Mistry; Jonathan P Bradfield; Ana M Valdes; Jose Bras; Aleksey Shatunov; Chen Lu; Buhm Han; Soumya Raychaudhuri; Steve Bevan; Maureen D Mayes; Lam C Tsoi; Evangelos Evangelou; Rajan P Nair; Struan F A Grant; Constantin Polychronakos; Timothy R D Radstake; David A van Heel; Melanie L Dunstan; Nicholas W Wood; Ammar Al-Chalabi; Abbas Dehghan; Hakon Hakonarson; Hugh S Markus; James T Elder; Jo Knight; Dan E Arking; Timothy D Spector; Bobby P C Koeleman; Cornelia M van Duijn; Javier Martin; Andrew P Morris; Rinse K Weersma; Cisca Wijmenga; Patricia B Munroe; John R B Perry; Jennie G Pouget; Yalda Jamshidi; Harold Snieder; Behrooz Z Alizadeh
Journal:  PLoS Med       Date:  2016-06-21       Impact factor: 11.069

7.  Commentary: Physical Functional Capacity and C-Reactive Protein in Schizophrenia.

Authors:  Ruth Elliesen; Andreas Walther
Journal:  Front Psychiatry       Date:  2018-01-26       Impact factor: 4.157

8.  A significant causal association between C-reactive protein levels and schizophrenia.

Authors:  Masatoshi Inoshita; Shusuke Numata; Atsushi Tajima; Makoto Kinoshita; Hidehiro Umehara; Masahito Nakataki; Masashi Ikeda; Souichiro Maruyama; Hidenaga Yamamori; Tetsufumi Kanazawa; Shinji Shimodera; Ryota Hashimoto; Issei Imoto; Hiroshi Yoneda; Nakao Iwata; Tetsuro Ohmori
Journal:  Sci Rep       Date:  2016-05-19       Impact factor: 4.379

9.  The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis.

Authors:  Erik Johnsen; Farivar Fathian; Rune A Kroken; Vidar M Steen; Hugo A Jørgensen; Rolf Gjestad; Else-Marie Løberg
Journal:  BMC Psychiatry       Date:  2016-03-14       Impact factor: 3.630

10.  Physical Functional Capacity and C-Reactive Protein in Schizophrenia.

Authors:  Michele Fonseca Vieira Szortyka; Viviane Batista Cristiano; Keila Maria Ceresér; Lenise Petter Francesconi; Maria Inês Lobato; Clarissa Gama; Paulo Belmonte-de-Abreu
Journal:  Front Psychiatry       Date:  2016-08-05       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.